The Lancet

Fatigue in people with primary biliary cholangitis: a position paper from the European Reference Network for Rare Liver Diseases

Given the unmet need of fatigue in primary biliary cholangitis (PBC), the PBC working group of the European Reference Network for Rare Liver Diseases assessed and summarised the current evidence ...
Mena FN

Primary Biliary Cholangitis Pipeline Drugs Report 2025: Transformative Research, Competitive Landscape, And Future Treatment Prospects

DelveInsight's,“ Primary Biliary Cholangitis Pipeline Insight 2025 ” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Primary Biliary Cholangitis pipeline landscape ...
Health on MSN

What To Know About Primary Biliary Cholangitis (PBC)

Medically reviewed by Jay N. Yepuri, MD PBC is a chronic liver disease that damages bile ducts and can lead to liver failure. You can get treatment for PBC to slow disease progression and manage ...
Medical News Today

Cholangitis vs. cholecystitis: What is the difference?

Cholangitis and cholecystitis are two conditions that share some similarities but have different causes and symptoms. Cholangitis affects the bile ducts, while cholecystitis affects the gallbladder.
Medscape

Non-Response to Obeticholic Acid May Predict Clinical Outcomes in Primary Biliary Cholangitis

In patients with primary biliary cholangitis, biochemical non-response to obeticholic acid as a second-line therapy may ...
Business Wire

Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis

– New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus in ...
Becker's ASC

FDA advisory committee to recommend approval of primary biliary cholangitis treatment drug: 4 takeaways

The FDA’s Gastrointestinal Drugs Advisory Committee voted unanimously to recommend accelerated approval of Intercept Pharmaceuticals’ Ocaliva. 1. Ocaliva (obeticholic acid) is intended for the ...
Business Wire

Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD), following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE ...
News Medical

Challenges in treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis

Primary sclerosing cholangitis (PSC) is a rare progressive liver disease that damages bile ducts and significantly increases the risk of bile duct cancer, particularly a type called cholangiocarcinoma ...
Nasdaq

Ipsen's Iqirvo Secures FDA Accelerated Approval For Primary Biliary Cholangitis Treatment

(RTTNews) - The U.S. Food and Drug Administration has granted accelerated approval for Iqirvo (elafibranor) 80 mg tablets for the treatment of primary biliary cholangitis or PBC in combination with ...
Morningstar

GSK’s Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights

EXTON, PA, July 17, 2025 (GLOBE NEWSWIRE) -- The treatment landscape for primary biliary cholangitis (PBC) has undergone a marked transformation over the past year, driven by the recent approvals of ...